Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.

Pharmacotherapy - 1 Mar 2014

Kwara Awewura, Cao Lei, Yang Hongmei, Poethke Pamela, Kurpewski Jaclynn, Tashima Karen T, Mahjoub Behrang D, Court Michael H, Peloquin Charles A

Abstract excerpt

STUDY OBJECTIVES: To identify factors associated with variability in rifampin plasma pharmacokinetics and explore the relationship between rifampin pharmacokinetics and change in efavirenz plasma pharmacokinetics with rifampin coadministration. METHODS: In this randomized, cross-over study, 12 healthy volunteers received either efavirenz 600 mg/day or efavirenz 600 mg with rifampin 600 mg/day for 8 days. After a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cyclopropanes

Share to Drug Interactions

Share to Liver-Specific Organic Anion Transporter 1

Share to Metabolic Clearance Rate

Share to Organic Anion Transporters

Source

Open in PubMed Open full text

Identifiers

PMID: 24420746
DOI: 10.1002/phar.1388
PMCID: PMC3947488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.PMID 24420746Read ↗

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Semantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.Semantic proximity Read ↗

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Semantic proximity Read ↗

Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Semantic proximity Read ↗

Population pharmacogenetic‐based pharmacokinetic modeling of efavirenz, 7‐hydroxy‐ and 8‐hydroxyefavirenzSemantic proximity Read ↗

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?Semantic proximity Read ↗

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Semantic proximity Read ↗

Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.Semantic proximity Read ↗

Clinical impact of patient population differences and genomic variation in efavirenz therapySemantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.